GMDA News and Press, Gamida Cell Ltd. From 03/20/23

Shawn Cline Tomasello to become Chairwoman, succeeding Chairman Robert I. Blum, who is resigning; Company focuses on upcoming regulatory milestone and commercialization Directors Dr. Naama Halevi-Davidov and Dr. Anat Cohen-Dayag also stepping down Gamida Cell Ltd. (Nasdaq: G...

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will host a conference call and live audio webcast on Monday, March 27, 2023, at 8:00 a.m. ET to review its fourth quarter and full year 2022 financial resu...

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Abbey Jenkins, President and Chief Executive Officer, will present its corporate highlights at the upcoming Oppenheimer 33 rd Annual Healthcare Conference on March ...

New data add to the body of evidence supporting efficacy of omidubicel, Gamida Cell’s lead product candidate, which has a target PDUFA action date with U.S. Food and Drug Administration (FDA) of May 1, 2023 New data for GDA-201, Gamida Cell’s natural killer (NK) cell the...

Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced the closing of a senior secured convertible term loan of $25 million with certain funds managed by Highbridge...

Recent company submission in response to FDA request extends PDUFA date by three months Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematological and solid cancers and other serious diseases, today pr...

Gamida Cell Ltd. (GMDA) Q3 2022 Results Conference Call November 14, 2022 08:00 AM ET Company Participants Heather DiVecchia - Director of IR & Corporate Communications Abigail Jenkins - President & CEO Ronit Simantov - CMO & Chief Scientific Officer ...

Gamida Cell press release ( NASDAQ: GMDA ): Q3 GAAP EPS of -$0.29 beats by $0.02 . Gamida Cell expects that its current total cash position, together with recent financing, will support the company’s ongoing operating activities into mid-2023, excluding the cost...

– Commercial launch preparations underway ahead of January 30, 2023 PDUFA target action date – – New data presented across multiple medical meetings to support the potential of omidubicel as an advanced cell therapy, including long term follow-up d...

Gamida Cell ( NASDAQ: GMDA ) is scheduled to announce Q3 earnings results on Sunday, November 13th, before market open. The consensus EPS Estimate is -$0.31 (+6.1% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 2 upward...